Regulatory Q&A Forum
Ask questions, share knowledge, and get help from the regulatory community
When evaluating the cost structure for an EU Responsible Person (RP) to ensure compliance with cosmetic regulations, what are the key service components and pricing models that a non-EU brand must ana...
When preparing a premarket submission for a connected medical device, such as a continuous glucose monitoring system or a software-based diagnostic tool, how should a sponsor approach cybersecurity do...
For non-EU based medical device and Software as a Medical Device (SaMD) manufacturers that process personal data of individuals in the European Union, what are the core functions and potential liabili...
When a non-EU manufacturer seeks to place a medical device on the European market, they must appoint an EU Authorized Representative (AR). While the fee structures for AR services can vary significant...
What key factors and due diligence steps should a non-EU medical device manufacturer implement when selecting an EU Authorized Representative (AR) under the Medical Device Regulation (EU) 2017/745? Be...
As foreign medical device establishments prepare for the FDA's Quality Management System Regulation (QMSR) to take effect on February 2, 2026, what constitutes a comprehensive strategy for selecting o...
For foreign medical device manufacturers preparing for the FDA's Quality Management System Regulation (QMSR) effective date of February 2, 2026, how should the selection of an FDA U.S. Agent be approa...
When evaluating external "Person Responsible for Regulatory Compliance (PRRC) as a Service" providers under the EU Medical Device Regulation (MDR), how can a startup or small manufacturer move beyond ...
When planning for 2026, how can a medical device manufacturer accurately forecast the cost of engaging an external 'Person Responsible for Regulatory Compliance' (PRRC) as a Service under the EU MDR, ...
For a non-EU manufacturer of a connected medical device, such as a Software as a Medical Device (SaMD) that processes personal health data from users in the European Union, navigating compliance can b...
When a non-EU company plans its compliance budget for 2026, what key factors should be considered to accurately estimate the cost of appointing a GDPR Article 27 Representative? While it is not possi...
While the introduction of broad EU regulations, such as the EU Deforestation Regulation (EUDR), highlights the need for a formal in-region presence for non-EU businesses, medical device manufacturers ...
For non-EU medical device manufacturers, appointing an EU Authorized Representative (AR) is a mandatory step for placing products on the European market under regulations like the MDR. While a common ...
With recent modernizations to the FDA's quality management system regulations for medical devices, how does the role and responsibility of a designated U.S. Agent evolve? Foreign establishments are re...
Given that FDA regulations require foreign medical device establishments to designate a U.S. Agent, how should manufacturers strategically select or re-evaluate their agent in light of the mandatory t...
When planning for future regulatory compliance under the EU MDR, particularly for 2026 and beyond, how can manufacturers effectively evaluate and budget for a "Person Responsible for Regulatory Compli...
When planning budgets for 2026, how can medical device manufacturers accurately forecast the cost of engaging a "Person Responsible for Regulatory Compliance (PRRC) as a Service" under the EU MDR? Bey...
When a manufacturer develops a novel Class II in vitro diagnostic (IVD) device that incorporates software, what are the primary regulatory considerations to address for a premarket submission? Sponso...
With the European Chemicals Agency (ECHA) advancing its universal PFAS restriction proposal, non-EU manufacturers of substances, mixtures, and articles containing per- and polyfluoroalkyl substances f...
With the FDA's transition from the Quality System Regulation (QSR) to the new Quality Management System Regulation (QMSR) becoming effective on February 2, 2026, how should foreign medical device manu...